Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 dose-ranging study in essential hypertension
NL-OMON31167Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan, valsartan and sacubitril in essential hypertension (8 arms), sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started Sep 2007; status: active, not recruiting.
02
Drugs
sacubitril + valsartanvalsartansacubitril
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NL-OMON31167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31167.